Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks
Abrir em Zacks
Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say

Bausch Health (BHC) reported $2.94 billion in revenue for the quarter ended September 2026, representing a year-over-year increase of 9.7%. EPS of $1.77 for the same period compares to $1.16 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $2.75 billion, representing a surprise of +7.11%. The company delivered an EPS surprise of +63.89%, with the consensus EPS estimate being $1.08.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Bausch performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Bausch + Lomb- Pharmaceuticals: $367 million compared to the $353.58 million average estimate based on two analysts. The reported number represents a change of +11.2% year over year. Revenues- Bausch + Lomb- Vision Care: $774 million versus the two-analyst average estimate of $770.83 million. The reported number represents a year-over-year change of +5.2%. Revenues- Bausch + Lomb- Surgical: $234 million compared to the $255.12 million average estimate based on two analysts. The reported number represents a change of +8.8% year over year. Revenues- Salix: $831 million versus $710.52 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +16.1% change. Revenues- International: $299 million versus $286.17 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.6% change. Revenues- Solta Medical: $165 million versus $169.11 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +17.9% change. Revenues- Diversified Products- Dentistry: $21 million compared to the $20.8 million average estimate based on two analysts. The reported number represents a change of -4.6% year over year. Revenues- Total Bausch + Lomb revenues: $1.38 billion versus the two-analyst average estimate of $1.38 billion. The reported number represents a year-over-year change of +7.3%. Revenues- Total Bausch Health (excl. B+L): $1.57 billion versus the two-analyst average estimate of $1.37 billion. The reported number represents a year-over-year change of +11.9%. Revenues- Diversified Products- Neuroscience: $146 million versus $112.32 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a 0% change. Revenues- Diversified Products- Dermatology: $86 million versus $53.22 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +16.2% change. Revenues- Diversified Products- Generics: $18 million compared to the $14.38 million average estimate based on two analysts. The reported number represents a change of +12.5% year over year.

View all Key Company Metrics for Bausch here>>>

Shares of Bausch have returned +8.8% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Bausch Health Cos Inc. (BHC): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research